Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapy

Prakash Ambady, Matthias Holdhoff, David Bonekamp, Fay Wong, Stuart A Grossman

Research output: Contribution to journalArticle

Abstract

Treatment of patients with newly diagnosed primary CNS lymphomas using high dose methotrexate regimens is reported to yield about 30% long term survivors with minimal neurotoxicity. As in other systemic large cell lymphomas, it is generally assumed that most relapses occur within 5 years of diagnosis. A retrospective review of the Johns Hopkins experience in 52 patients treated between 1995 and 2008 yielded 19 patients (37%) who achieved a complete response and were followed for over 5 years. Four of these patients remained progression-free for over 10 years. However, two of these long-term survivors have now relapsed over 10 years after their initial diagnosis. An analysis of progression and overall survival does not reveal a plateau suggesting that even patients who have not recurred for over 10 years remain at high risk for relapse after treatment with single agent high dose methotrexate.

Original languageEnglish (US)
Pages (from-to)393-398
Number of pages6
JournalCNS oncology
Volume4
Issue number6
DOIs
StatePublished - Jan 1 2015

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapy'. Together they form a unique fingerprint.

  • Cite this